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Class of Antiretroviral
Therapy and CD4+ T Cell
Count Recovery:
Independence Questioned
To the Editor—I would like to con-
gratulate Khanna et al. [1] for their study,
which investigated risk factors associated
with poor increases in the CD4+ T cell
count in a Swiss cohort of HIV-1–infected
patients. A priori knowledge of these fac-
tors would be very useful in clinical prac-
tice to aid in the selection of the combi-
nation antiretroviral therapy (ART)
regimen that is most likely to optimize
immunologic recovery.
In terms of increases in the CD4+ T cell
count, however, Khanna et al. [1] reported
“similar” (nonsignificant) effects for
boosted protease inhibitors (PIs; 452 re-
cipients; median increase, 343 cells/mL),
nonnucleoside reverse-transcriptase in-
hibitors (NNRTIs; 251 recipients; median
increase, 255 cells/mL), and nonboosted
PIs (2590 recipients; median increase, 310
cells/mL). In contrast, a large, systematic
review [2] reported significant differences
in CD4+ T cell count among recipients of
these ART classes after 48 weeks of treat-
ment: for boosted PIs (1002 recipients),
the increase was 200 cells/mL; for NNRTIs
(6705 recipients), the increase was 173
cells/mL; and for PIs (4602 recipients), the
increase was 179 cells/mL. Importantly, the
superior and statistically significant effect
on the CD4+ T cell count associated with
boosted PI ART was also noted in mul-
tivariate analysis [2]. It remains uncertain
whether the discordant conclusions of
these 2 studies resulted from differences
in statistical power, from the statistical
model used (Cox vs. linear regression), or
from bias adjustment.
I would also like to point out that, in
the 2 studies cited in the Discussion sec-
tion to support the absence of a statisti-
cally significant difference in effect be-
tween boosted PIs and NNRTIs, the one
randomized study [3] included atazanavir
without ritonavir—that is, a nonboosted
PI.
In my opinion, the results reported by
Khanna et al. [1] should not undermine
the fact that PIs [4], but not NNRTIs,
modulate activation of peripheral blood
CD4+ T cells and decrease their suscepti-
bility to apoptosis, both in vitro and in
vivo. This occurs independently of HIV
replication inhibition [5]. Of note, low
doses of ritonavir increase PI exposure to
these cells, without additional hepatic tox-
icity, compared with administration of
nonboosted PIs [6].
Of interest, the authors reported that
hepatitis C virus (HCV)–coinfected indi-
viduals were significantly less likely to have
an increase in the CD4+ T cell count. They
speculated, “Whether coinfection with
HCV or a poorer adherence to ART in
this group of primarily injection drug
users is responsible for this observation
remains to be shown” [1, p. 1099]. Of
note, this group of patients was also sig-
nificantly less likely to be prescribed
boosted-PI ART (21% were HIV-HCV
coinfected, compared with 35% of pa-
tients in the nonboosted PI group). Ar-
guably, you cannot adhere to a regimen
that your physician did not prescribe to
you. It would be interesting to know
whether HCV infection status remained
significant in the subgroup of patients who
had access to more-potent boosted PIs.
In conclusion, the superior effect of
commencement of an ART regimen that
includes boosted PIs should be considered
in the context of risk factors for poor like-
lihood of recovery of the CD4+ T cell
count, including among HIV-HCV–coin-
fected persons.
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To the Editor—Parienti [1] highlights
important study results and findings re-
garding the effect of different combined
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antiretroviral treatment (cART) modalities
on increases in the CD4+ T cell count and
on immune reconstitution. In fact, many
studies indicate that boosted protease in-
hibitor (PI) therapy, compared with non-
nucleoside reverse-transcriptase inhibitor
(NNRTI) therapy, leads to greater in-
creases in the CD4+ T cell count [2]. It is
likely that the discrepancy between those
data and the data from our study resulted
from a larger number of included patients
in the study by Bartlett et al. [2]. In that
study, 53 trials were included in the anal-
ysis, for a total of 14,264 patients in 90
treatment arms. As a consequence, smaller
differences between the study groups in
the median CD4+ T cell count after 48
weeks became statistically significant.
However, it is unlikely that these small
differences between treatment groups in
the CD4+ T cell count will have clinical
consequences, such as a higher proportion
of opportunistic infections.
Of importance, most of these studies
reported that older age, lower baseline
CD4+ T cell count, and low baseline viral
loads were followed by lower increases in
the CD4+ T cell count, regardless of
whether those increases were measured in
absolute numbers (compared with base-
line values) or whether the study measured
the percentage of patients who reached
specific CD4+ T cell count thresholds. Be-
cause many patients (∼50%) who initiate
combination ART switch treatment regi-
men during the first year of treatment [3],
there has been a lack of long-term studies
of immune recovery in the context of spe-
cific treatments or treatment modalities. A
recent study in Switzerland found that 36
first-line regimens were initially adminis-
tered and that, in 53% of cases, these reg-
imens were changed during the first year
[4]. Therefore, it is likely that questions
such as which regimen is best for immune
reconstitution can only be answered
through large trials conducted over long
periods. With this in mind, we cannot ex-
clude the possibility that patients with sub-
optimal CD4+ T cell count recoveries
switched treatments earlier in the course
of therapy, leading to a “leveling off,”
compared with different treatments re-
ceived by patients remaining in the anal-
ysis [5].
It is impossible to judge whether this
could have introduced a bias—in partic-
ular, bias against the effect of boosted
PIs—in one direction or another. As noted
by Parienti [1], we did not assess our pa-
tients with regard to the lower viral load
threshold of 50 copies/mL, because with
use of this criterion, the number of pa-
tients would have been too low to assess
different unchanged treatments over such
long periods. It would also be difficult to
examine in larger cohorts, because “blips”
may contribute to measurements150 cop-
ies/mL. In our study, 34.4% of patients
developed detectable HIV-1 RNA levels af-
ter month 6. In patients for whom HIV-
1 RNA levels were consistently undetect-
able during the 48-month period and who
received boosted PI therapy, an increase
in the CD4+ T cell count of 393 cells/mL
was noted, compared with 274 cells/mL
among patients with consistently unde-
tectable levels who received NNRTI ther-
apy—a difference of 119 cells/mL in favor
of boosted PIs. However, the number of
patients was too small and the interquar-
tile ranges for CD4+ T cell counts were too
large to reach statistical significance in a
multivariate regression model that com-
pared immune responses. In addition, the
median increases in the CD4+ T cell counts
did not differ significantly. As pointed out
by Parienti [1], treatment with PIs may
have had a positive effect on the increase
in the CD4+ T cell count, because apo-
ptosis of these cells did not occur. This is
a reasonable explanation for the slightly
higher—but not significantly different—
median CD4+ T cell count in the boosted
PI group. It was not our aim to examine
specific treatment combinations for the
contribution of individual drugs to im-
mune reconstitution (i.e., for each drug
combination in conjunction with differ-
ences in the nucleoside reverse-transcrip-
tase inhibitor backbone) [6, 7]. However,
we confirmed that zidovudine treatment
led to significantly lower increases in the
CD4+ T cell count. In addition, hepatitis
C virus–coinfected patients who received
boosted PIs had significantly lower CD4+
T cell counts at 48 months (410 vs. 593
cells/mL; ).Pp .03
As acknowledged by Parienti [1], our
main finding—that CD4+ T cell count in-
creases were similar among persons who
received different cART modalities—is
meaningful [5]. Over the long term, most
HIV–infected cART recipients experience
normalization of CD4+ T cell counts [8].
In that study, patients with low baseline
CD4+ T cell counts (!200 cells/mL) had
significant increases in the CD4+ T cell
counts even after 5 years of cART. The
study by Mocroft et al. [8] did not define
which specific cART regimen was associ-
ated with the fastest normalization of the
CD4+ T cell count; however, the fact that
patients who experienced optimal viral re-
sponses to treatment had increases in their
CD4+ T cell counts, even up to 5 years
after commencement of cART, supports
our findings. Thus, longer durations of
cART and longer observation periods may
yield or reveal similar increases in the
CD4+ T cell count. As stated above,
switches in the regimen are frequently ob-
served during the first year, and patients
with more significant increases in the
CD4+ T cell count may have been selected.
On the other hand, our findings provide
an important piece of information for cli-
nicians: if a patient tolerates a particular
treatment regimen, and if the CD4+ T cell
count increases as expected during the first
year of therapy, additional increases are to
be expected.
We would like to support the notion
that, for a given patient, it would be very
useful to select an optimal regimen in
terms of immunological recovery with
prior knowledge of the risks. At this mo-
ment, for individual patients, it is difficult
to assess specific risk factors and to de-
termine which treatment, in the long term,
is most beneficial in terms of immune re-
constitution. Finally, we should acknowl-
edge that individual immune responses
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Figure 1. MRI of the patient’s cervical cord. The T2 sequence demonstrated severe cord swelling
suggestive of cord infarction.
(such as cellular immune responses to spe-
cific pathogens), which are often deter-
mined on the basis of numeric and func-
tional CD4+ T cell count recovery, might
not depend completely on CD4+ T cell
counts attained. The importance of spe-
cific immune responses was demonstrated
in a recent study of the development of
brain lymphoma in HIV-infected patients
that occurred despite normal CD4+ T cell
counts [9].
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in an HIV-Infected Patient
To the Editor—A 41-year-old woman
was transferred to our institution with a
2-day history of fever, headache, neck
pain, and progressive flaccid quadripa-
resis. She had a background of HIV in-
fection diagnosed 15 years earlier, with no
prior AIDS-defining illness. Three weeks
before presentation, her CD4+ T cell count
was 155 cells/mL (her nadir; CD4+ cell per-
centage, 7%), and her HIV RNA level was
6000 copies/mL. One week later, antiret-
rovial therapy (ART) was changed from
lamivudine, nevirapine, and abacavir to
lamivudine, raltegravir, and ritonavir-
boosted atazanavir because of immuno-
logical and virological failure.
The patient was febrile (temperature,
38.6C), drowsy, confused, and hypo-
phonic and had neck stiffness and a flaccid
quadriparesis. Reflexes other than triceps
jerks were absent. Sensory findings were
not evaluable. Results of cranial nerve ex-
amination were normal. Six vesicular le-
sions were noted on her anterior chest
examination.
Results of brain CT were normal, and
lumbar puncture revealed xanthochromic
CSF. Opening pressure was 15 cm H20;
the patient’s protein concentration was
extremely elevated, at 39.0 g/L (normal
range, 0.15–0.4 g/L), her glucose level was
2 mmol/L (normal range, 2.5–4.5 mmol/
L), and her RBC count was 1400 cells/mL,
with 40 polymorphs and 2 lymphocytes.
Her serum glucose level was 6.9 mmol/L.
Gram stain revealed no organisms. The
patient’s CD4+ T cell count had decreased
to 83 cells/mL (CD4 cell percentage,
9%). Assessment of HIV load was not
performed.
Intravenous dexamethasone, acyclovir,
